Clearmind announces the initiation of a CMND-100 manufacturing program to address its upcoming clinical trial.

[ad_1]

Vancouver, November 23 2022 (Global News) — Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Be clear.“or”the company“), a biotech company focused on discovering and developing novel psychedelic therapies to address major undertreated health problems, today announced the clinical batch production of its novel psychedelic-derived drug candidate, MEAI-based molecule – CMND. 100.

The manufactured batches will be used in the Company’s upcoming first-in-human (FIH) clinical trial evaluating its proprietary drug candidate compound CMND-100 for the treatment of alcohol use disorder (AUD).

After MEAI’s incorporation process, Manufactured under GMP (Good Manufacturing Process) specifications to meet FDA requirements. The successful pre-production of the MEAI drug product, which was used in the company’s pre-clinical studies designed to evaluate the safety of the company’s innovative compounds, led to clinical batch production.

Clearmind CEO Dr. Adi Zuloff-Shani said, “Clearmind continues its progress toward the FIH clinical trial. “This milestone is in line with other achievements we’ve had in a short period of time. Non-clinical data produced to date; Our MEAI-based treatment demonstrates the potential to treat a wide range of addictive and compulsive behaviors, such as AUD.”

“Like other addictions, AUD is a chronic, relapsing brain disorder characterized by an impaired ability to stop or control alcohol consumption,” she added. “Alcohol consumption is the third most common preventable cause of death in the United States, with nearly 6% suffering from this condition.”

The Company previously announced that it has completed a highly positive Investigational New Drug Application (“pre-IND”) meeting with the US Food and Drug Administration (“FDA”) to discuss the development of CMND-100.

About Clearmind Medicine Inc

Clearmind is a pharmaceutical biotechnology company focused on solving intractable health problems, including alcohol use disorder. Its primary purpose is to conduct research into psychoactive compounds and their use as controlled drugs; to attempt to sell commercially as foods or supplements.

The company’s intellectual property portfolio currently includes seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will continue to have rights regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind’s shares are listed for trading on Nasdaq under the symbol “CMNDCanadian Securities under the symbol “,CMND“And the Frankfurt Stock Exchange” under the symbolCWY“

Please contact us for more information.

investor relations;

Email: [email protected]

Telephone: (604) 260-1566

general inquiries;

[email protected]

www.Clearmindmedicine.com

Forward-looking statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. “Expectations,” “Expectations,” Words such as “intends,” “plans,” “believes,” “expectations,” “estimates” and similar expressions or variations are intended to identify forward-looking statements. for example, The drug candidate that the company derives from its innovative passion; the company’s upcoming FIH clinical trial; and the Company is using forward-looking statements when discussing future correspondence with the FDA. Forward-looking statements are not historical facts; management’s current expectations; Most of them are uncertain by their very nature because they are based on beliefs and estimates. Such expectations; Beliefs and estimates are expressed in good faith. However, expectations of management; There can be no assurance that beliefs and projections will be realized; Actual results may differ materially from those expressed or implied in forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a detailed description of the risks and uncertainties affecting the Company; including without limitation the risks described in Reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”). The Company’s final prospectus filed with the SEC on November 16, 2022 (Registration No. 333-265900). Forward-looking statements speak only as of the date of the statement. Company actual results; subsequent events or circumstances; It undertakes no obligation to update forward-looking statements for changes in assumptions or other factors that may affect the extent to which forward-looking information is used. If the Company updates one or more forward-looking statements; No conclusion should be drawn that the Company will make any additional updates with respect to these or other forward-looking statements. References and links to websites are provided for convenience and information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the content of third party websites.